9/4/2013 9:12:43 AM
Chippenham, UK – 4 September 2013: Vectura Group plc (LSE: VEC) (“Vectura”), advises that the following presentations will be made at the European Respiratory Society (ERS) Annual Congress 2013, being held in Barcelona, Spain, 7-11 September 2013.
Data to be presented at ERS by Novartis will include the latest analyses from the Phase III IGNITE clinical trial program on Ultibro® Breezhaler® (QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule)1,2,3. QVA149 is a once-daily investigational fixed dose combination of a long-acting beta2-adrenergic agonist (LABA) and a long-acting muscarinic antagonist (LAMA), that received a positive opinion for approval from the European Medicine Agency’s (EMA) Committee for the Human use of Medicinal Products (CHMP) in July 2013 as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
New exacerbation, lung function and safety data will also be presented on Seebri® Breezhaler® (glycopyrronium 44 mcg delivered dose equivalent to 50 mcg metered dose per capsule)4,5 and efficacy data on Onbrez® Breezhaler® (indacaterol maleate 150 mcg)6, which are the monotherapy components of QVA149.
Alongside abstract presentations, Novartis will also be holding the following two symposia relating to COPD at ERS:
- Rethinking the treatment landscape of COPD: September 8 (17:15-19:15 CET, Room 3.13)
- Dual bronchodilation: A new treatment option for COPD patients: September 9 (17:15-19:15 CET, Room 3.13)
Vectura will be hosting a dinner on Monday 9 September for analysts and investors with a number of key opinion leaders.
For further details please contact firstname.lastname@example.org.
ERS is the largest respiratory meeting in the world, with delegates attending from more than 100 countries. All abstracts and details on timings can be accessed through the ERS website: http://www.erscongress2013.org.
Vectura Group plc +44 (0)1249 667700
Chris Blackwell, Chief Executive
Karl Keegan, Corporate Development Director
FTI Consulting +44 (0)20 7831 3113
John Dineen / Ben Atwell
Help employers find you! Check out all the jobs and post your resume.
comments powered by